Bahi Amine, Al Mansouri Shamma, Al Memari Elyazia, Al Ameri Mouza, Nurulain Syed M, Ojha Shreesh
Department of Anatomy, College of Medicine & Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
Department of Anatomy, College of Medicine & Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
Physiol Behav. 2014 Aug;135:119-24. doi: 10.1016/j.physbeh.2014.06.003. Epub 2014 Jun 13.
Recent evidence suggests that the cannabinoid receptor subtype 2 (CB2) is implicated in anxiety and depression disorders, although few systematic studies in laboratory animals have been reported. The aim of the current experiments was to test the effects of the CB2 receptor potent-selective agonist β-caryophyllene (BCP) in animals subjected to models of anxiolytic- and antidepressant-like effects. Therefore effects of BCP (50mg/kg) on anxiety were assessed using the elevated plus maze (EPM), open field (OF), and marble burying test (MBT). However for depression, the novelty-suppressed feeding (NSF), tail suspension test (TST), and forced swim tests (FST) were used. Results indicated that adult mice receiving BCP showed amelioration of all the parameters observed in the EPM test. Also, BCP significantly increased the time spent in the center of the arena without altering the general motor activity in the OF test. This dose was also able to decrease the number of buried marbles and time spent digging in the MBT, suggesting an anti-compulsive-like effect. In addition, the systemic administration of BCP reduced immobility time in the TST and the FST. Finally, BCP treatment decreased feeding latency in the NSF test. Most importantly, pre-administration of the CB2 receptor antagonist AM630, fully abrogated the anxiolytic and the anti-depressant effects of BCP. Taken together, these preclinical results suggest that CB2 receptors may provide alternative therapeutic targets for the treatment of anxiety and depression. The possibility that BCP may ameliorate the symptoms of these mood disorders offers exciting prospects for future studies.
最近的证据表明，大麻素受体2型（CB2）与焦虑和抑郁障碍有关，尽管在实验动物中进行的系统性研究报道较少。当前实验的目的是测试CB2受体强效选择性激动剂β-石竹烯（BCP）对焦虑样和抑郁样效应动物模型的影响。因此，使用高架十字迷宫（EPM）、旷场试验（OF）和埋大理石试验（MBT）评估了BCP（50mg/kg）对焦虑的影响。然而，对于抑郁，使用了新奇抑制摄食试验（NSF）、悬尾试验（TST）和强迫游泳试验（FST）。结果表明，接受BCP的成年小鼠在EPM试验中观察到的所有参数均有所改善。此外，BCP显著增加了在旷场中央停留的时间，而未改变OF试验中的总体运动活动。该剂量还能够减少MBT中埋藏大理石的数量和挖掘时间，表明具有抗强迫样效应。此外，全身给予BCP可减少TST和FST中的不动时间。最后，BCP治疗可缩短NSF试验中的摄食潜伏期。最重要的是，预先给予CB2受体拮抗剂AM630可完全消除BCP的抗焦虑和抗抑郁作用。综上所述，这些临床前结果表明，CB2受体可能为焦虑和抑郁的治疗提供替代治疗靶点。BCP可能改善这些情绪障碍症状的可能性为未来的研究提供了令人兴奋的前景。
